Change in number of shares and votes in Camurus

Lund, Sweden — 30 December 2024 — During December 2024, a total of 70,250 employee stock options in Camurus’ employee stock options program ESOP 2021/2024 have been exercised for subscription of the corresponding number of shares.

As a result of the exercises made under ESOP 2021/2024, the number of shares and votes has increased by 70,250.

Prior to the exercise, the total number of shares in Camurus amounted to 58,808,768 corresponding to 58,808,768 votes. As of 30 December 2024, the total number of shares in Camurus amounts to 58,879,018, corresponding to 58,879,018 votes.

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com  

Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com

About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal^® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disorders, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

This information is information that Camurus AB is obliged to make public pursuant to Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act. The information was submitted for publication at 7:00 am CET on 30 December 2024.